Prévisions du marché européen des produits thérapeutiques contre les maladies infectieuses jusqu\'en 2030 – Analyse régionale – par classe de médicaments (antiviraux, antibactériens, antifongiques et autres), indication (VIH, hépatite, tuberculose, grippe, VPH et autres), voie d\'administration (Oral, parentéral, topique et autres) et canal de distribution (pharmacies hospitalières, pharmacies de détail et autres)
L\'accent croissant sur le financement et la R&D dans le domaine thérapeutique des maladies infectieuses stimule le marché européen de la thérapeutique contre les maladies infectieuses
La recherche et le développement (R&D) sont une partie essentielle de l’activité des sociétés biopharmaceutiques et pharmaceutiques. La R&D leur permet de lancer de nouveaux produits pour plusieurs applications thérapeutiques au potentiel médical et commercial important. En outre, les principaux acteurs du marché investissent dans la R&D pour développer des technologies améliorées et accroître leur part de revenus.
Afin de créer des solutions aux problèmes de santé les plus importants auxquels l\'Europe et le reste du monde sont actuellement confrontés, l\'Union européenne investit dans la recherche, la technologie et l\'innovation. La Commission européenne a ouvert la voie en promouvant la recherche, en particulier celle liée à l\'immunité et à la gestion des maladies infectieuses. Entre 2007 et 2019, plus de 4,3 milliards de dollars (4 milliards) ont été alloués à l’étude des maladies infectieuses. En outre, Horizon Europe, la prochaine initiative de financement de l\'UE (2021-2027) pour la recherche et l\'innovation (R&I), continuera à soutenir la R&I sur les maladies infectieuses, notamment celles associées à la pauvreté, celles qui sont négligées et celles qui sont (re- )émergent.
Horizon Europe est un programme dédié au soutien à la recherche et à l\'innovation. Afin de surmonter les barrières entre les régions et d\'établir des collaborations tangibles, le programme met fortement l\'accent sur la coopération entre les universités, les communautés scientifiques, l\'industrie, en particulier les petites et moyennes entreprises, et les particuliers. Le programme de travail sur la santé décrit les options de financement dans le cadre d\'Horizon Europe pour la recherche liée aux maladies infectieuses ainsi qu\'à la préparation et à la réponse aux pandémies. Ainsi, l’accent croissant mis sur la R&D et le financement des thérapies contre les maladies infectieuses stimulent la croissance du marché des thérapies contre les maladies infectieuses.
Aperçu du marché européen des produits thérapeutiques pour les maladies infectieuses
Le marché européen des produits thérapeutiques pour les maladies infectieuses est segmenté en Allemagne, au Royaume-Uni, en France, en Italie, en Espagne et dans le reste de l\'Europe. L’Europe occupe une position importante sur le marché mondial des traitements contre les maladies infectieuses et devrait enregistrer un TCAC notable au cours de la période 2022-2030. La région connaît une incidence accrue de maladies virales chroniques et une forte demande pour le développement de nouveaux médicaments antiviraux. Avec 15,79 milliards de dollars financés de 2007 à 2019 par le biais du 7e programme-cadre et d\'Horizon 2020 et les 1,1 milliards de dollars promis pour la recherche sur le COVID-19, l\'Europe joue un rôle crucial dans le financement et la coordination de la recherche sur les maladies infectieuses. Selon l\'Institut Robert Koch, en Allemagne, entre 400 000 et 600 000 patients souffrent chaque année d\'une infection nosocomiale, parmi lesquels 10 000 à 15 000 en meurent. Les problèmes typiques auxquels sont confrontés les prestataires de soins de santé sont les infections du site opératoire, les infections des voies urinaires et la pneumonie. La demande d\'agents anti-infectieux en Allemagne augmente considérablement, en raison de l\'augmentation de la population gériatrique, de la prévalence croissante des maladies virales chroniques et de la demande croissante de production de nouvelles molécules pour les domaines thérapeutiques viraux afin de répondre à des conditions non satisfaites. L\'Allemagne est l\'un des principaux pays en termes de fabrication d\'agents antiviraux et de potentiel de croissance en Europe en raison de la haute qualité de ses produits finis. Par exemple, Atriva Therapeutics GmbH, une société biopharmaceutique, a développé l\'ATR-002 pour traiter les patients atteints de COVID-19 dans le cadre d\'une étude de phase II visant à bloquer la propagation virale du SRAS-CoV-2. Par conséquent, en raison des facteurs mentionnés ci-dessus, le marché devrait connaître une croissance significative dans le pays.
Revenus et prévisions du marché européen des produits thérapeutiques pour les maladies infectieuses jusqu\'en 2030 (millions de dollars américains)
Segmentation du marché européen des produits thérapeutiques pour les maladies infectieuses
Le marché européen des produits thérapeutiques pour les maladies infectieuses est classé en classe de médicaments. , indication, voie d\'administration, canal de distribution et pays.
En fonction de la classe de médicaments, le marché européen des produits thérapeutiques contre les maladies infectieuses est segmenté en antiviraux, antibactériens, antifongiques et autres. Le segment des antiviraux détenait la plus grande part de marché en 2022.
En termes d\'indication, le marché européen des produits thérapeutiques contre les maladies infectieuses est segmenté en VIH, hépatite, tuberculose, grippe, VPH et autres. Le VIH détenait la plus grande part de marché en 2022.
En fonction de la voie d\'administration, le marché européen des produits thérapeutiques contre les maladies infectieuses est segmenté en traitements oraux, parentéraux, topiques et autres. Le segment oral détenait la plus grande part de marché en 2022.
En termes de canal de distribution, le marché européen des produits thérapeutiques contre les maladies infectieuses est segmenté en pharmacies hospitalières, pharmacies de détail et autres. Les pharmacies hospitalières détenaient la plus grande part de marché en 2022.
Par pays, le marché européen des produits thérapeutiques pour les maladies infectieuses est segmenté en Allemagne, au Royaume-Uni, en France, en Italie, en Espagne et dans le reste de l\'Europe. L\'Allemagne a dominé la part de marché européenne des produits thérapeutiques contre les maladies infectieuses en 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc et Shionogi & Co Ltd comptent parmi les principales sociétés opérant sur le marché européen des produits thérapeutiques contre les maladies infectieuses.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Europe Analysis
5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Infectious Disease Therapeutics Market - Country Analysis
10.1 Europe Infectious Disease Therapeutics Market
10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Europe Infectious Disease Therapeutics Market Segmentation
Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.